TT

Turn Therapeutics Inc.

TTRX·NASDAQ

$6.42

+1.1%
HealthcareBiotechnology

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$191.24M
EPS-0.2300
P/E Ratio-16.95
Earnings Date09/02/2026
t

Turn Therapeutics Inc. Street Expectations Map

TTRX · NASDAQ

No Target Data

No analyst price targets available for ttrx.

t

Turn Therapeutics Inc. Forward Estimates of Revenue

TTRX · NASDAQ
Latest Revenue
0.00
FY 2025
Avg Estimate
200.00K
FY 2026
Estimate Range
200.00K - 200.00K
Analyst Spread

Forward Growth Analysis

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

Estimate Spread0%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookNeutral

Mixed signals—some positive indicators offset by concerns about growth or uncertainty.

t

Turn Therapeutics Inc. Forward Estimates of Net Income

TTRX · NASDAQ
Latest Net Income
-3.19M
FY 2025
Avg Estimate
-1.37M
FY 2026
Estimate Range
-1.37M - -1.37M
Analyst Spread

Forward Growth Analysis

Projected Growth+57.0%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

Estimate Spread0%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

t

Turn Therapeutics Inc. Forward Estimates of EPS

TTRX · NASDAQ
Latest EPS
-0.23
FY 2025
Avg Estimate
$-0.10
FY 2026
Estimate Range
$-0.10 - $-0.10
Analyst Spread

Forward Growth Analysis

Projected Growth+56.5%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

Estimate Spread0%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

t

Turn Therapeutics Inc. Forward Estimates of EBIT

TTRX · NASDAQ
Latest EBIT
-5.86M
FY 2025
Avg Estimate
0.00
FY 2026
Estimate Range
0.00 - 0.00
Analyst Spread

Forward Growth Analysis

Projected Growth+100.0%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

OutlookNeutral

Mixed signals—some positive indicators offset by concerns about growth or uncertainty.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

t

Turn Therapeutics Inc. Forward Estimates of EBITDA

TTRX · NASDAQ
Latest EBITDA
-5.81M
FY 2025
Avg Estimate
0.00
FY 2026
Estimate Range
0.00 - 0.00
Analyst Spread

Forward Growth Analysis

Projected Growth+100.0%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

OutlookNeutral

Mixed signals—some positive indicators offset by concerns about growth or uncertainty.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

t

Turn Therapeutics Inc. Forward Estimates of SG&A Expense

TTRX · NASDAQ
Latest SG&A Expense
5.59M
FY 2025
Avg Estimate
0.00
FY 2026
Estimate Range
0.00 - 0.00
Analyst Spread

Forward Growth Analysis

Projected Growth-100.0%

Significant contraction projected—major business challenges or industry disruption likely.

Analyst Coverage1 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

t

Turn Therapeutics Inc. Insider Positioning

TTRX · NASDAQ

During the last 12 months, there has been no insider trading activity reported for TTRX.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Neutral

No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.

Insider Participation

No Activity

No insider trading activity reported from any insiders in the past year.